SELLAS Life Sciences Group, Inc.
(NASDAQ : SLS)

( )
SLS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
1.43%89.631.3%$877.94m
AMGNAmgen Inc.
0.40%191.891.2%$550.47m
GILDGilead Sciences, Inc.
0.50%64.920.9%$461.62m
BIIBBiogen Inc.
-29.23%226.881.3%$457.10m
ONCESpark Therapeutics, Inc.
-0.20%113.2711.2%$443.03m
REGNRegeneron Pharmaceuticals, Inc.
-0.72%402.592.6%$280.51m
ILMNIllumina, Inc.
1.24%319.213.5%$280.06m
VRTXVertex Pharmaceuticals Incorporated
1.43%182.561.9%$232.81m
SRPTSarepta Therapeutics, Inc.
2.27%126.6615.4%$211.90m
EXASExact Sciences Corporation
1.70%92.0225.3%$191.93m
ALXNAlexion Pharmaceuticals, Inc.
1.94%134.212.0%$186.57m
BPTHBio-Path Holdings, Inc.
-14.05%18.48190.1%$182.12m
AAgilent Technologies, Inc.
1.34%82.001.6%$143.35m
IONSIonis Pharmaceuticals, Inc.
0.36%80.508.3%$105.13m
BMRNBioMarin Pharmaceutical Inc.
0.91%90.784.3%$95.05m

Company Profile

SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutic for a broad range of indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. The company was founded on April 3, 2006 and is headquartered in New York, NY.